BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Achieves Several Key Milestones in 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, has so far reached several key milestones in 2021. According to a recent article, these include: “raising $23 million in a bought deal short form prospectus public offering that closed in February this year. On the technology side, MCURF launched the minimum viable product (‘MVP’) of iSTRYM in Q3 2021. On the drug development and research side, the company synthesized ibogaine and has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. The company has also filed patent applications for two routes of chemical synthesis of ibogaine.” Additionally, in a recent Bell2Bell podcast episode, MCURF CEO and President Kelsey Ramsden noted that although ibogaine, a psychedelic drug, is very chemically complex and difficult to build in the lab, the MCURF team was able to synthesize it fully. For the remainder of 2021, “The company intends to spend about six months iterating the iSTRYM product in anticipation of a full commercial product launch in Q1 2022. Mind Cure Health also aims to scale up its ibogaine production to provide the psychedelic drug to researchers. Further, it is working on new research initiatives.”

To view the full article, visit https://ibn.fm/rDsl0

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.